6.
Johnson T, Parker R, Johnson J, Graham B
. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol. 2003; 170(4):2037-45.
DOI: 10.4049/jimmunol.170.4.2037.
View
7.
Hancock G, Speelman D, Heers K, Bortell E, Smith J, Cosco C
. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol. 1996; 70(11):7783-91.
PMC: 190848.
DOI: 10.1128/JVI.70.11.7783-7791.1996.
View
8.
Polack F, Alvarez-Paggi D, Libster R, Caballero M, Blair R, Hijano D
. Fatal enhanced respiratory syncytial virus disease in toddlers. Sci Transl Med. 2021; 13(616):eabj7843.
PMC: 10712289.
DOI: 10.1126/scitranslmed.abj7843.
View
9.
Hammad H, Lambrecht B
. Barrier Epithelial Cells and the Control of Type 2 Immunity. Immunity. 2015; 43(1):29-40.
DOI: 10.1016/j.immuni.2015.07.007.
View
10.
Leiva-Juarez M, Kolls J, Evans S
. Lung epithelial cells: therapeutically inducible effectors of antimicrobial defense. Mucosal Immunol. 2017; 11(1):21-34.
PMC: 5738267.
DOI: 10.1038/mi.2017.71.
View
11.
Russo R, Quesniaux V, Ryffel B
. Homeostatic chemokines as putative therapeutic targets in idiopathic pulmonary fibrosis. Trends Immunol. 2023; 44(12):1014-1030.
DOI: 10.1016/j.it.2023.10.003.
View
12.
Li C, Zhou X, Zhong Y, Li C, Dong A, He Z
. A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease. J Immunol. 2016; 196(4):1721-31.
DOI: 10.4049/jimmunol.1502103.
View
13.
Lee Y, Ko E, Kim K, Lee Y, Hwang H, Kwon Y
. A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus. Virology. 2019; 534:1-13.
PMC: 6642440.
DOI: 10.1016/j.virol.2019.05.010.
View
14.
Sparer T, Matthews S, Hussell T, Rae A, Melero J, Openshaw P
. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J Exp Med. 1998; 187(11):1921-6.
PMC: 2212312.
DOI: 10.1084/jem.187.11.1921.
View
15.
Li Y, Wang X, Blau D, Caballero M, Feikin D, Gill C
. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022; 399(10340):2047-2064.
PMC: 7613574.
DOI: 10.1016/S0140-6736(22)00478-0.
View
16.
Boyoglu-Barnum S, Todd S, Chirkova T, Barnum T, Gaston K, Haynes L
. An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology. 2015; 483:117-25.
PMC: 4516680.
DOI: 10.1016/j.virol.2015.02.035.
View
17.
Gartlan C, Tipton T, Salguero F, Sattentau Q, Gorringe A, Carroll M
. Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses. Front Immunol. 2022; 13:882972.
PMC: 9014240.
DOI: 10.3389/fimmu.2022.882972.
View
18.
Castilow E, Meyerholz D, Varga S
. IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J Immunol. 2008; 180(4):2376-84.
DOI: 10.4049/jimmunol.180.4.2376.
View
19.
Johnson T, Graham B
. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol. 1999; 73(10):8485-95.
PMC: 112868.
DOI: 10.1128/JVI.73.10.8485-8495.1999.
View
20.
Lindsley A, Schwartz J, Rothenberg M
. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol. 2020; 146(1):1-7.
PMC: 7194727.
DOI: 10.1016/j.jaci.2020.04.021.
View